Cost-effectiveness of ERT in adult patients with Pompe disease
The number of orphan drugs, i.e. drugs for rare diseases, is vastly growing. These drugs are often associated with high drug prices. Cost-effectiveness studies… Read more »
Tim Kanters (PhD) works as a researcher at the institute for Medical Technology Assessment, Erasmus University Rotterdam, the Netherlands. His PhD dissertation was on health technology assessment of orphan drugs, with a particular focus on health economics aspects of ERT in Pompe disease.
Latest posts by Tim Kanters (see all)
- Cost-effectiveness of ERT in adult patients with Pompe disease - 19th December 2017